<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02040272</url>
  </required_header>
  <id_info>
    <org_study_id>MARS2</org_study_id>
    <nct_id>NCT02040272</nct_id>
  </id_info>
  <brief_title>MARS 2: A Feasibility Study Comparing (Extended) Pleurectomy Decortication Versus no Pleurectomy Decortication in Patients With Malignant Pleural Mesothelioma</brief_title>
  <acronym>MARS2</acronym>
  <official_title>A Study to Determine if it is Feasible to Recruit Into a Randomised Trial Comparing (Extended) Pleurectomy Decortication Versus no Pleurectomy Decortication in Patients With Malignant Pleural Mesothelioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Brompton &amp; Harefield NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Papworth Hospital NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Royal Brompton &amp; Harefield NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mesothelioma is a cancer of the thin membrane that lines the chest and abdomen. Around 2300
      people in the UK are diagnosed with mesothelioma each year and the average survival is
      approximately 17 months. Exposure to asbestos is the most common cause although the cancer
      does not usually become apparent until 30-40 years after exposure. Anti-cancer drugs
      (chemotherapy) are usually given to help treat mesothelioma and sometimes lung-sparing
      surgery (pleurectomy decortication) surgery is undertaken. However, it is not known if this
      surgery, in addition to chemotherapy, can increase survival and improve the quality of life
      for patients. The aim of the MARS2 study is to determine if it is feasible to enrol patients
      with mesothelioma into a study randomising them to chemotherapy only or chemotherapy and
      lung-sparing surgery. Patients will be followed up regularly at their usual clinic visits for
      to 5 years. Patients will be asked to complete a Quality of Life Questionnaire at these
      visits. Tissue samples will be taken at the time of diagnosis and at surgery (if they are
      randomised to surgery) for mesothelioma research central storage and blood samples will be
      taken at the clinic visits up to 12 months for mesothelioma research central storage. If we
      can show the feasibility of recruitment we will apply to continue the study to include more
      patients in order to determine if lung-sparing surgery improves survival and quality of life
      for mesothelioma patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ability to randomise 50 patients</measure>
    <time_frame>24 months</time_frame>
    <description>Ability to randomise 50 patients within the first 24 months or the ability to recruit 25 patients within any 6 month period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival from the time point of randomisation</measure>
    <time_frame>Follow up for up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as assessed using QLQ 30 and LC-13 scales</measure>
    <time_frame>Follow up for up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Mesothelioma</condition>
  <arm_group>
    <arm_group_label>Surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Extended) pleurectomy decortication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no surgery</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>(Extended) pleurectomy decortication</intervention_name>
    <arm_group_label>Surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Histological confirmation of mesothelioma, 2. Disease confined to one hemi-thorax.

        Exclusion Criteria:

          -  1. Unable to give informed consent, 2. Patients unwilling to be randomised, 3. Extent
             of disease not deemed to be surgically resectable, 4. ECOG status 2 or more, 5.
             Patients with predicted pre-operative FEV1 or TLco less than 20%, 6. Patients with
             severe heart failure (EF less than 30%), 7. Patients with end stage kidney failure
             requiring dialysis, 8. Patients with liver failure, 9. Patients who are participating
             in another interventional clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Lim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Brompton &amp; Harefield NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric Lim</last_name>
    <email>e.lim@rbht.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jane Elliott</last_name>
    <email>Jane.elliott5@nhs.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Burton Hospitals NHS Foundation Trust</name>
      <address>
        <city>Burton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manjusha Keni</last_name>
    </contact>
    <investigator>
      <last_name>Manjusha Keni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Papworth</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Rintoul</last_name>
    </contact>
    <investigator>
      <last_name>Robert Rintoul</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiff</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malgorzata Kornaszewska</last_name>
    </contact>
    <investigator>
      <last_name>Malgorzata Kornaszewska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Colchester</name>
      <address>
        <city>Colchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dakshinamoorthy Muthukumar</last_name>
    </contact>
    <investigator>
      <last_name>Dakshinamoorthy Muthukumar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Derby</name>
      <address>
        <city>Derby</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manjusha Keni</last_name>
    </contact>
    <investigator>
      <last_name>Manjusha Keni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leeds</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Milton</last_name>
    </contact>
    <investigator>
      <last_name>Richard Milton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Leicester NHS Trust</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dean Fennell</last_name>
    </contact>
    <investigator>
      <last_name>Dean Fennell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Marsden</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanjay Popat</last_name>
    </contact>
    <investigator>
      <last_name>Sanjay Popat</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wythenshawe</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Taylor</last_name>
    </contact>
    <investigator>
      <last_name>Paul Taylor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Tees</name>
      <address>
        <city>Middlesbrough</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Talal Mansy</last_name>
    </contact>
    <investigator>
      <last_name>Talal Mansy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Tyneside NHS Foundation Trust</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liz Fuller</last_name>
    </contact>
    <investigator>
      <last_name>Liz Fuller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Gwent</name>
      <address>
        <city>Newport</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alina Ionescu</last_name>
    </contact>
    <investigator>
      <last_name>Alina Ionescu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheffield Teaching Hospitals NHS Foundation Trust</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Edwards</last_name>
    </contact>
    <investigator>
      <last_name>John Edwards</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clatterbridge</name>
      <address>
        <city>Wirral</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Pope</last_name>
    </contact>
    <investigator>
      <last_name>Anthony Pope</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Cross</name>
      <address>
        <city>Wolverhampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Morgan</last_name>
    </contact>
    <investigator>
      <last_name>Ian Morgan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2013</study_first_submitted>
  <study_first_submitted_qc>January 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2014</study_first_posted>
  <last_update_submitted>May 11, 2017</last_update_submitted>
  <last_update_submitted_qc>May 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

